Study of a new chemotherapy combined with capecitabine for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial is testing whether adding a new form of chemotherapy (mitoxantrone hydrochloride liposome injection) to capecitabine (a standard chemotherapy pill) helps people with advanced nasopharyngeal carcinoma live longer or control their cancer better than capecitabine alone. You may be eligible if your cancer has progressed after platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a confirmed diagnosis of nasopharyngeal carcinoma that has spread or come back.
- Your cancer did not respond to or stopped responding to standard chemotherapy that includes a platinum drug (like cisplatin).
- You have at least one measurable tumor that can be evaluated, and it hasn't been previously treated with radiation (or has clearly grown after radiation).
- You are in reasonably good health (able to carry on daily activities and light work) and your organs are functioning well enough.
- If you are of childbearing age, you must agree to use effective contraception during the trial and for at least 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
This trial tests whether taking two oral drugs (capecitabine and toripalimab) after your first treatment can keep your nasopharyngeal cancer from growing. It is for people whose cancer has spread and responded well to initial therapy, and aims to see if this maintenance approach improves outcomes.
This study tests a new combination of two drugs (JMT101 and a liposomal form of mitoxantrone) for people with nasopharyngeal cancer that has not responded to standard treatments like immune therapy and chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
Hear when a new Recurrent Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.